Unexpected lack of effect of COVID-19 lockdown on migraine in patients taking anti-CGRP therapies Galcanezumab quality of life benefits similar in Japanese and Caucasian patients Reversion from chronic to episodic migraine persists during long term erenumab treatment Potential advantages of targeting both CGRP and PACAP in chronic migraine and post-traumatic headache Nurtec (rimegepant) Phase 2/3 data in migraine prevention published NICE recommends Aimovig (erenumab) use on NHS after appeal Dual blockade of meningeal nociceptors demonstrated with atogepant/ onabotulinumtoxinA combination NICE confirms Emgality (galcanezumab) availability on NHS

CGRP in cluster headache

22 January 2020 | Videos

In the third in his series of videos about the future of CGRP therapies, Peter Goadsby describes the research that led to the approval of galcanezumab for the treatment of episodic cluster headache and looks forward to better understanding of how treatment can be optimised for patients most likely to benefit.

Educational Partners and Supporters (others pending) Amgen

Amgen

Editorial PolicyCGRP Forum is an expert resource for clinicians and healthcare professionals working with migraine patients. All patients should discuss their medication with their healthcare professional. Unless otherwise indicated, opinions expressed in the CGRP Education and Research Forum are those of the contributors. Although every effort is made to ensure accuracy and avoid mistakes, no liability on the part of the CGRP Forum, the editors or the editorial board is accepted for the consequences of any misleading or inaccurate information.

© 2021 | Privacy Policy | Editorial Policy | Governance | Disclaimer Statement | Partnership & Outreach |